REG - AstraZeneca PLC - Late-Stage Pipeline Conference Call <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

02/12/2015 07:11

RNS Number : 6560H
AstraZeneca PLC
02 December 2015
LATE-STAGE PIPELINE CONFERENCE CALL 
FOR INVESTORS AND ANALYSTS
AstraZeneca PLC ("AstraZeneca", "the Company") will today host a conference call for investors and analysts. This will focus on key potential medicines within the late-stage pipeline and will provide further details on the progress made in 2015 and the anticipated news flow in 2016. No material new information will be included; the call is intended to offer additional insight on the pipeline.
The event will be led by Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer, alongside AstraZeneca experts from each of the Company's main therapy areas and will take place at 16:00 - 17:30 GMT (11:00 - 12:30 EST).
The dial-in details for the conference call are as follows:
UK
0800 694 2370
US
866 977 7645
International
+44 1452 557749
Sweden
0200 883 079
Code
79258160
The accompanying presentation will be available for download at astrazeneca.com/investors one hour prior to the start of the call. A link to the live audio webcast will also be available at this address. An indexed version and transcript of the webcast will be published in due course.
A replay of the call can be accessed from 17:30 GMT today via the following numbers:
UK
0800 953 1533
US
866 247 4222
International
+44 1452 550000
Code
79258160
Reporting Calendar
The Company intends to publish its full-year financial results on 4 February 2016.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit: www.astrazeneca.com
CONTACTS
Media Enquiries

Esra Erkal-Paler
UK/Global
+442076048030
Vanessa Rhodes
UK/Global
+44 20 7604 8037
Karen Birmingham
UK/Global
+44 20 7604 8120
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677

Investor Enquiries
UK

Thomas Kudsk Larsen
Oncology
+44 7818 524185
Eugenia Litz
RIA
+44 7884 735627
Nick Stone
CVMD
+44 7717 618834
Craig Marks
Finance 
+44 7881 615764
Christer Gruvris
Consensus Forecasts
+44 7827 836825
US


Lindsey Trickett
Oncology, ING
+1 240 543 7970
Mitchell Chan
Oncology
+1 240 477 3771
Toll-Free

+1 866 381 7277
Key: RIA - Respiratory, Inflammation & Autoimmunity, CVMD - Cardiovascular & Metabolic Disease, 
ING - Infection, Neuroscience & Gastrointestinal
02 December 2015
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCTBBJTMBMMTBA